CTOs on the Move

International Center for Toxicology and Medicine

www.ictm.com

 
International Center for Toxicology and Medicine is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ictm.com
  • 2301 Research Blvd
    Rockville, MD USA 20850
  • Phone: 301.519.0300

Executives

Name Title Contact Details

Similar Companies

CORIA Laboratories

CORIA Laboratories, Ltd. is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Flowr Corporation

The Flowr Corporation is a global cannabis company that exists to cultivate better people, plants and products. Based in Toronto, we operate globally in Canada, Europe and Australia. In Canada, our operating campus in Kelowna, BC is situated in the Okanagan Valley, an epicentre of cannabis cultivation. This campus produces recreational and medicinal cannabis from a purpose-built, GMP-designed indoor cultivation facility, an outdoor and greenhouse cultivation site, and (soon to open) state-of-the-art R&D facility. Internationally, The Flowr Corporation will meet growing global medicinal cannabis demand through its subsidiary Holigen. Licensed to cultivate in Portugal, Holigen will operate GMP-designed cultivation facilities in both Portugal and Australia. Our goal is to be the #1 choice of consumers and patients alike, and our established experts in cannabis cultivation, regulated industries and consumer goods aim to meet that goal responsibly, everywhere we operate.

Health Solutions Network

Health Solutions Network is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Forma Therapeutics

At FORMA, patients are our purpose. We are dedicated to delivering transformative medicines to patients with cancer and rare diseases. We are a fully-integrated, privately-held clinical stage biopharmaceutical company. A leader in metabolism, epigenetics and protein homeostasis focused on the discovery, development and commercialization of transformative medicines. Our proprietary R&D platform combines deep biology insight, chemistry expertise and clinical development capabilities to create differentiated drug candidates. We have delivered high-value clinical candidates to our partners and generated a broad proprietary portfolio of internal programs, ranging from pre-clinical to pivotal-stage, with the potential to provide profound patient benefit in hematologic, oncologic and metabolic indications.